Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.

Erythroid promoter confines FGF2 expression to the marrow after hematopoietic stem cell gene therapy and leads to enhanced endosteal bone formation.

Fibroblast growth factor-2 (FGF2) has been demonstrated to be a promising osteogenic factor for treating osteoporosis. Our earlier study shows that transplantation of mouse Sca-1(+) hematopoietic stem/progenitor cells that are engineered to express a modified FGF2 leads to considerable endosteal/tra...

Full description

Bibliographic Details
Main Authors: Xianmei Meng, David J Baylink, Matilda Sheng, Hongjie Wang, Daila S Gridley, K-H William Lau, Xiao-Bing Zhang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3356341?pdf=render

Internet

http://europepmc.org/articles/PMC3356341?pdf=render

Similar Items